Evidence map›Paper›PMID 29572505›Full record

Trial reportLeukemia2018

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

S Rule, W Jurczak, M Jerkeman, C Rusconi, M Trneny, F Offner, D Caballero, C Joao, M Witzens-Harig, G Hess and 8 more

Abstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

S RulePlymouth University Medical School, Plymouth, UK. Simon.Rule@nhs.net.ORCID http://orcid.org/0000-0001-8937-6351
W JurczakDepartment of Hematology, Jagiellonian University, Krakow, Poland.
M JerkemanSkånes University Hospital, Lund University, Lund, Sweden.
C RusconiHematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
M TrnenyIst Dept Medicine, Charles University General Hospital, Prague, Czech Republic.
F OffnerDepartement Oncologie, UZ Gent, Ghent, Belgium.
D CaballeroInstituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
C JoaoInstitutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal.
M Witzens-HarigKlinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany.
G HessDepartment of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany.
I Bence-BrucklerThe Ottawa Hospital, General Campus, Ottawa, ON, Canada.
S-G ChoSeoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea.ORCID http://orcid.org/0000-0002-5429-4839
C ThieblemontAPHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France.
W ZhouJanssen Research & Development, Raritan, NJ, USA.
T HenningerJanssen Research & Development, Raritan, NJ, USA.
J GoldbergJanssen Research & Development, Raritan, NJ, USA.
J VermeulenJanssen Research & Development, Leiden, The Netherlands.
M DreylingDepartment of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Salvage TherapyAdenineAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesHumansInternational AgenciesLymphoma, Mantle-CellPiperidinesPrognosisPyrazolesPyrimidinesSirolimusSurvival RateAdenineibrutinibPiperidinesPyrazolesPyrimidinesSirolimustemsirolimus

Identifiers

PMID29572505
PMCPMC6087720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.